ClinicalTrials.Veeva

Menu

Test-Retest Reliability And Validation For End-Tidal Carbon Dioxide Measurement (PetCO2) During Rest And Low-Loaded Steady State Work Using A Portable Capnograph.

L

Linköping University (LiU)

Status

Invitation-only

Conditions

Ventilatory Physiology
VO2max
Cardiopulmonary Exercise Test
End-Tidal Carbon Dioxide

Study type

Observational

Funder types

Other

Identifiers

NCT07326449
2025-01777-01

Details and patient eligibility

About

The goal of this observational study is to investigate exhaled carbon dioxide measuring during rest and low-loaded work using a portable device (capnograph) and standard of care apparatus during a cardiopulmonary exercise test (CPET) in healthy volunteers. The study aims to answer:

How reliable is exhaled end-tidal carbon dioxide measurement for an individual over time using both standard of care apparatus and a portable device during an ergometer test?

Do the measurements correlate between the portable device and standard of care apparatus?

How do changes in breathing instructions and placement of sampling cannula affect the measurements from the portable device (capnograph)?

How is the reliability over time of other well established values from a cardio pulmonary exercise test?

Participants will be asked to perform a modified cardiopulmonary exercise test on an ergometer twice, separated in time (1-4 weeks). Measurements are sampled alternating standard of care apparatus and a portable capnograph at rest and during low-loaded work.

Full description

Study summery The study is an experimental methodological investigation involving research participants who are essentially healthy. Individuals who consent to participate and meet all inclusion criteria without any exclusion criteria will be eligible for the study.

Each participant will perform a modified maximal exercise test on an ergometer on two separate occasions (1 to 4 weeks). The ergospirometric exercise test will be performed on a ergometer (eBike Basic, GE Medical Systems, GmbH), with PetCO₂ measured at rest while seated on the bike and at various predetermined steady state levels during low to moderate loading. Participants will then continue the protocol with a ramping workload to maximal exertion. The test will be terminated when the participant no longer can maintain the pedaling cadence (60 rpm) or develops predefined abnormal symptoms.

Gas analysis will be conducted using breath-by-breath technology (Jaeger Oxycon Pro or Vyntus CPX; Viasys Healthcare) and the hand held monitor (Capnostream35, Medtronic) connected to the nasal cannula.

Two test leaders (medically trained, one of whom is a physician) will oversee the exercise test, with one managing the ergospirometric equipment and the other handling PetCO₂ measurement via the handheld monitor.

Data from the handheld capnograph will be recorded on a specially coded (study ID) protocol form. Ergospirometric data including symptom ratings will be stored in a patient database under the participant's personal identity number.

The exercise tests will be medically reviewed.

For data processing, coded protocol data from each participant will be compiled together with ergospirometric data in a dedicated database. Data will be handled in coded form, manually processed, and extrapolated for group-level analyses.

Additional information from the study protocol will include gender, age, height, and weight. Also, smoking habits, cardiovascular and pulmonary comorbidities and related medications, and any symptoms during exertion will be recorded.

Primary Research Question What is the reliability of PetCO₂ measurement in the same individual, using a handheld PetCO₂ monitor with nasal cannula compared to a closed respiratory gas analysis system (ergospirometry), during repeated measurements on two different days, at rest and at various levels of exertion during a cycle ergometer test?

Secondary Research Questions What is the agreement between PetCO₂ measured with a closed respiratory gas analysis system (ergospirometry) and a handheld PetCO₂ monitor with nasal cannula, at rest and during physical exercise at different exertion levels in a cycle ergometer test? For the handheld chandheld PetCO₂ monitor, how are the measured PetCO₂ values affected depending on whether sampling is done nasally or orally, and whether the subject is instructed to breathe freely or only through the nose or mouth? What is the reliability of other established measures obtained from ergospirometry, such as peak oxygen uptake and ventilatory efficiency, measured using the same ergospirometric equipment as in the questions above?

Hypotheses PetCO₂ values do not differ statistically significantly between two different measurement occasions at the same workload and measurement method, regardless of sampling method.

There is no systematic bias in PetCO₂ measurement with the handheld monitor compared to ergospirometric measurement at rest or during low to moderate intensity cycling.

There is no systematic bias due to different sampling methods of EtCO₂ using the handheld device.

Variation in PetCO₂ from both handheld and ergospirometry measurements is not clinically significantly greater than the variation in other established ergospirometric variables.

Sample Size The sample size was determined through an equivalence analysis for the primary research question, where the hypothesis is that the difference between two measurements (taken on two separate occasions at the same workload) falls within a clinically insignificant margin. The null hypothesis is that there is a clinically significant difference between the occasions.

A clinically relevant difference is defined as 0.1 kPa, with a standard deviation of the difference between occasions of 0.1 kPa, power of 80%, and significance level of 0.05. Based on these parameters, 16 participants are required. Accounting for an expected dropout rate of 20% , 20 participants will be recruited, corresponding to 40 completed exercise tests.

Statistical Methods Collected data on PetCO₂ are numerical and will be analyzed using parametric or non-parametric methods depending on the distribution. Descriptive analysis will be used to characterize the study population, presenting mean and standard deviation or alternatively median and interquartile range.

For reliability assessment, intraclass correlation coefficient (ICC) analysis will be performed. Additionally, the coefficient of variation (COV%) will be reported for each measurement. Bland-Altman analysis will be used to assess agreement with ergospirometric measurements, as well as to evaluate different sampling methods using the handheld device.

Missing Data Occasional missing values will not be imputed.

Outliers Apparent erroneous values, defined as values lying beyond 1.5 times the interquartile range below Q1 or above Q3, will be excluded during data processing.

Adverse events Any sensitive personal data, primarily concerning the individual's health, disclosed by a research participant may necessitate the study personnel to refer the individual to the appropriate healthcare provider.

The study is conducted within a regular hospital setting for exercise testing evaluation, with access to emergency medical expertise and equipment. Study personnel are licensed healthcare professionals with extensive experience and knowledge in managing acute, including life-threatening, medical conditions.

There is a possibility that unexpected findings or signs of illness may be identified during the exercise test. In such cases, the individual will be referred to the appropriate healthcare authority for further assessment.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults aged between 18 and 70 years.
  • Proficient in spoken and written Swedish.
  • Capable of cycling on an exercise bicycle.

Exclusion criteria

  • Current symptoms of upper respiratory tract infection or fever within the past 5 days
  • Obesity (BMI > 30 kg/m²)
  • Known respiratory pattern disorders/hyperventilation syndrome
  • More than mild asthma or other pulmonary diseases
  • Cardiovascular disease (except for hypertension with or without treatment, mild heart valve disease at most, previous pericarditis > 12 months prior)
  • Known pregnancy
  • Presence of exertion-related symptoms such as chest pain, dizziness, syncope, arrhythmia, or abnormal shortness of breath

Trial design

20 participants in 1 patient group

Cohort 1 - Healthy volunteers
Description:
Cohort 1 consists of 20 study participants eligable with the inclusion and exclusion criteria.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems